Zacks: Brokerages Anticipate Teladoc Health Inc (TDOC) Will Announce Quarterly Sales of $109.89 Million

Wall Street brokerages forecast that Teladoc Health Inc (NYSE:TDOC) will post sales of $109.89 million for the current quarter, according to Zacks Investment Research. Eleven analysts have made estimates for Teladoc Health’s earnings, with the highest sales estimate coming in at $111.20 million and the lowest estimate coming in at $107.55 million. Teladoc Health posted sales of $68.65 million in the same quarter last year, which suggests a positive year-over-year growth rate of 60.1%. The business is scheduled to issue its next quarterly earnings results on Wednesday, November 7th.

According to Zacks, analysts expect that Teladoc Health will report full year sales of $411.42 million for the current year, with estimates ranging from $406.77 million to $413.40 million. For the next year, analysts anticipate that the company will post sales of $545.41 million, with estimates ranging from $526.00 million to $560.16 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover Teladoc Health.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, August 1st. The health services provider reported ($0.37) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.38) by $0.01. Teladoc Health had a negative net margin of 37.78% and a negative return on equity of 19.10%. The company had revenue of $94.60 million for the quarter, compared to the consensus estimate of $91.56 million. During the same quarter in the prior year, the company earned ($0.28) EPS. Teladoc Health’s quarterly revenue was up 112.1% on a year-over-year basis.

Several equities analysts recently weighed in on the stock. KeyCorp increased their price target on shares of Teladoc Health from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Friday, September 28th. Chardan Capital increased their price target on shares of Teladoc Health from $73.00 to $86.00 and gave the stock a “buy” rating in a report on Friday, August 3rd. Robert W. Baird increased their price target on shares of Teladoc Health from $50.00 to $65.00 and gave the stock a “neutral” rating in a report on Wednesday, July 25th. Canaccord Genuity reiterated a “buy” rating and issued a $70.00 price target on shares of Teladoc Health in a report on Thursday, August 2nd. Finally, Citigroup reiterated a “buy” rating and issued a $95.00 price target on shares of Teladoc Health in a report on Friday, September 28th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. Teladoc Health has a consensus rating of “Buy” and a consensus price target of $79.79.

In other news, insider Lewis Levy sold 1,284 shares of the firm’s stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $77.00, for a total transaction of $98,868.00. Following the sale, the insider now owns 1,284 shares of the company’s stock, valued at approximately $98,868. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Mark Hirschhorn sold 35,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 25th. The stock was sold at an average price of $80.42, for a total transaction of $2,814,700.00. Following the sale, the vice president now directly owns 10,000 shares in the company, valued at approximately $804,200. The disclosure for this sale can be found here. Insiders have sold a total of 283,710 shares of company stock worth $19,864,135 in the last ninety days. Corporate insiders own 3.95% of the company’s stock.

Several large investors have recently made changes to their positions in the company. CWM LLC lifted its position in shares of Teladoc Health by 2.1% during the 2nd quarter. CWM LLC now owns 53,632 shares of the health services provider’s stock valued at $3,113,000 after buying an additional 1,078 shares in the last quarter. Swiss National Bank lifted its position in shares of Teladoc Health by 1.7% during the 1st quarter. Swiss National Bank now owns 94,400 shares of the health services provider’s stock valued at $3,804,000 after buying an additional 1,600 shares in the last quarter. Amalgamated Bank lifted its position in shares of Teladoc Health by 22.3% during the 2nd quarter. Amalgamated Bank now owns 9,472 shares of the health services provider’s stock valued at $550,000 after buying an additional 1,724 shares in the last quarter. LPL Financial LLC lifted its position in shares of Teladoc Health by 18.6% during the 1st quarter. LPL Financial LLC now owns 11,431 shares of the health services provider’s stock valued at $461,000 after buying an additional 1,791 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Teladoc Health by 4.8% during the 1st quarter. The Manufacturers Life Insurance Company now owns 42,984 shares of the health services provider’s stock valued at $1,732,000 after buying an additional 1,984 shares in the last quarter.

NYSE:TDOC traded down $4.83 during midday trading on Monday, hitting $71.00. The company’s stock had a trading volume of 2,530,500 shares, compared to its average volume of 1,230,026. Teladoc Health has a fifty-two week low of $27.30 and a fifty-two week high of $89.05. The company has a current ratio of 3.14, a quick ratio of 3.14 and a debt-to-equity ratio of 0.58. The company has a market cap of $6.01 billion, a PE ratio of -43.03 and a beta of 0.57.

About Teladoc Health

Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Further Reading: What is a stock buyback?

Get a free copy of the Zacks research report on Teladoc Health (TDOC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply